Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
indiana blog main
indiana top stories
6
×
life sciences
national blog main
6
×
new york blog main
new york top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
amgen
cancer
deals
fda
gene therapy
medicare
merck
novartis
pfizer
spark therapeutics
alnylam pharmaceuticals
amicus therapeutics
What
patients
6
×
drug
bio
roundup
fda
gene
market
moves
therapy
type
acquisitions
advantages
albert
approval
aren’t
bar
becker
bid
biggest
billions
boehringer
bourla
brings
cancer
ceo
company
crispr
developers
diabetes
dollars
drugs
eaton
eisai
eli
expand
expect
fallen
flags
future
gamble
Language
unset
unknown
Current search:
patients
×
" national blog main "
×
" indiana top stories "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More